← Back to Search

Behavioral Intervention

Sense2Quit App for Smoking Cessation in HIV

N/A
Waitlist Available
Led By Rebecca Schnall, PhD, MPH
Research Sponsored by Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks after baseline (or quit date if later than baseline visit)
Awards & highlights

Study Summary

This trial tests if a mobile app helps people living with HIV quit smoking.

Who is the study for?
This trial is for people living with HIV who smoke, are at least 18 years old, own an Android smartphone, and can understand English. They should be willing to quit smoking within a month and not currently using any nicotine replacement or other smoking cessation aids. Pregnant or breastfeeding individuals cannot participate.Check my eligibility
What is being tested?
The Sense2Quit App is being tested in this study to see if it's feasible and effective for helping people living with HIV to stop smoking. The trial will involve 60 participants who will use the app as part of a pilot randomized controlled trial.See study design
What are the potential side effects?
Since this trial involves the use of an app for smoking cessation, there may not be direct side effects from the intervention itself; however, quitting smoking can lead to withdrawal symptoms such as irritability, cravings, and difficulty concentrating.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks after baseline (or quit date if later than baseline visit)
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks after baseline (or quit date if later than baseline visit) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants With Biochemically Verified 7-day Point Prevalence Smoking/Tobacco Abstinence

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Intervention (App Arm)Experimental Treatment1 Intervention
Participants randomized to the intervention arm will receive access to the Sense2Quit App (A multi-component intervention that links a smartphone app to a smartwatch to provide real-time quit reminders to curtail relapses and avoid potential triggers), standard smoking cessation counseling, and nicotine replacement therapy.
Group II: ControlActive Control1 Intervention
Participants randomized to the control arm will receive standard smoking cessation counseling and referral to quitline.

Find a Location

Who is running the clinical trial?

Columbia UniversityLead Sponsor
1,438 Previous Clinical Trials
2,448,735 Total Patients Enrolled
Case Western Reserve UniversityOTHER
300 Previous Clinical Trials
246,562 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,717 Previous Clinical Trials
40,953,304 Total Patients Enrolled

Media Library

Sense2Quit App (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05609032 — N/A
Human Immunodeficiency Virus Infection Research Study Groups: Intervention (App Arm), Control
Human Immunodeficiency Virus Infection Clinical Trial 2023: Sense2Quit App Highlights & Side Effects. Trial Name: NCT05609032 — N/A
Sense2Quit App (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05609032 — N/A
~13 spots leftby Nov 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top